Johan M. Kros
Impact in
- Genetics top 0.01%
- Glioma Diagnosis and Treatment
- Cancer Research top 0.2%
- Cancer, Hypoxia, and Metabolism
- MicroRNA in disease regulation
Papers in
- Genetics 152
- Glioma Diagnosis and Treatment 151
-
- Cancer, Hypoxia, and Metabolism 14
- Co-authors
- Martin J. van den Bent (82 shared papers)Thierry Gorlia (31 shared papers)Michael Weller (8 shared papers)Roger Stupp (8 shared papers)Jacoline E. C. Bromberg (9 shared papers)Monika E. Hegi (3 shared papers)Johannes Andreas Hainfellner (5 shared papers)R.O. Mirimanoff (3 shared papers)
- Journals
- Neuro-Oncology (26 papers)Journal of Neuropathology & Experimental Neurology (18 papers)Acta Neuropathologica (16 papers)Journal of Clinical Oncology (12 papers)Cancer (11 papers)
- Partner nations
- NetherlandsUnited StatesBelgium
In The Last Decade
Johan M. Kros
303 papers receiving 27.4k citations
Johan M. Kros's Hit Papers
Peers
Comparison fields: 5 of 161
- Genetics 15.6k
- Cancer Research 5.2k
- Neurology 3.3k
- Pulmonary and Respiratory Medicine 4.6k
- Molecular Biology 9.0k
Countries citing papers authored by Johan M. Kros
This map shows the geographic impact of Johan M. Kros's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Johan M. Kros with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Johan M. Kros more than expected).
Fields of papers citing papers by Johan M. Kros
This network shows the impact of papers produced by Johan M. Kros. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Johan M. Kros. The network helps show where Johan M. Kros may publish in the future.
Co-authors
The 25 scholars most cited alongside Johan M. Kros, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 312 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma Hit paper breakdown → | 2005 | 5960 |
| 2 | Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951 Hit paper breakdown → | 2012 | 958 |
| 3 | Intertumoral Heterogeneity within Medulloblastoma Subgroups Hit paper breakdown → | 2017 | 894 |
| 4 | Subgroup-specific structural variation across 1,000 medulloblastoma genomes Hit paper breakdown → | 2012 | 731 |
| 5 | Intrinsic Gene Expression Profiles of Gliomas Are a Better Predictor of Survival than Histology Hit paper breakdown → | 2009 | 573 |
| 6 | Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis Hit paper breakdown → | 2011 | 554 |
| 7 | I nternational S ociety of N europathology‐ H aarlem C onsensus G uidelines for N ervous S ystem T umor C lassification and G rading Hit paper breakdown → | 2014 | 483 |
| 8 | 2009 | 478 | |
| 9 | Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study Hit paper breakdown → | 2016 | 403 |
| 10 | Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO) Hit paper breakdown → | 2016 | 392 |
| 11 | cIMPACT‐NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT‐Utrecht meeting on future CNS tumor classification and grading Hit paper breakdown → | 2020 | 390 |
| 12 | cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas Hit paper breakdown → | 2020 | 383 |
| 13 | 2010 | 338 | |
| 14 | 2017 | 306 | |
| 15 | 2016 | 275 | |
| 16 | 2017 | 269 | |
| 17 | 2003 | 251 | |
| 18 | 2014 | 250 | |
| 19 | Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study Hit paper breakdown → | 2021 | 246 |
| 20 | 2016 | 234 |
About Johan M. Kros
Johan M. Kros is a scholar working on Genetics, Cancer Research, Neurology, Molecular Biology and Pulmonary and Respiratory Medicine, having authored 312 papers that have together received 28.1k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (151 papers), Brain Metastases and Treatment (29 papers), Meningioma and schwannoma management (19 papers), Chromatin Remodeling and Cancer (14 papers), Cancer, Hypoxia, and Metabolism (14 papers), Neuroblastoma Research and Treatments (13 papers), Hedgehog Signaling Pathway Studies (13 papers) and Pituitary Gland Disorders and Treatments (12 papers). The work is most often cited by research in Genetics (15.6k citations), Cancer Research (5.2k citations), Neurology (3.3k citations), Pulmonary and Respiratory Medicine (4.6k citations) and Molecular Biology (9.0k citations). Johan M. Kros has collaborated with scholars based in Netherlands, United States and Belgium. Frequent co-authors include Martin J. van den Bent, Thierry Gorlia, Michael Weller, Roger Stupp, Jacoline E. C. Bromberg, Monika E. Hegi, Johannes Andreas Hainfellner, R.O. Mirimanoff, Peter Hau and John Gregory Cairncross. Their work appears in journals such as Neuro-Oncology, Journal of Neuropathology & Experimental Neurology, Acta Neuropathologica, Journal of Clinical Oncology and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.